siRNA Therapeutics
-
Phio Pharma Concludes Enrollment in Phase 1b Trial of INTASYL siRNA PH-762
Phio Pharmaceuticals completed Phase 1b enrollment for PH-762, an siRNA therapeutic targeting skin cancers. Initial data from 18 patients, primarily with cutaneous squamous cell carcinoma (cSCC), showed promising results: six complete responses, two near-complete, and two partial responses in cSCC patients. A Merkel cell carcinoma patient exhibited a partial response. No dose-limiting toxicities were observed. Further pathology results from the highest dose cohort are expected in Q1 2026. This early data suggests potential efficacy and tolerability in a small cohort.
